Topic: drug delivery technology
AI in drug development is among the hottest buzzwords in biopharma right now, but real progress is hampered by lack of expertise and access.
Two phase 3 studies of J&J’s antihistamine contact lens showed it reduced feelings of itchy eyes after 15 minutes and for as long as 12 hours.
Wednesday, March 27, 2019
Technology is impacting every aspect of our lives, and the life sciences industry is no different—it is changing the way companies operate. The need to embrace change is an imperative for these companies to stay competitive and continue to deliver on patient needs.
Impel’s championing of nasal delivery of drugs has been rewarded with new financing that will help it advance three drugs through the clinic.
Clearside Biomedical has cratered after revealing its top drug failed a phase 3 trial in retinal vein occlusion, a common cause of vision loss.
Wednesday, November 28, 2018
This webinar will benefit executives at Biotech and Pharmaceutical companies interested in learning more about 505(b)(2), the pathway of choice.
Royal Philips and Ypsomed plan to install digital, at-home adherence tracking across a line of connected injection and infusion systems.
Aprecia Pharmaceuticals, LLC
Tuesday, October 16, 2018
3DP can offer formulation advantages such as better molecule protection, adjustable powder layers and flexibility in dose loading for adaptive clinical trials.
Eye disease specialist Ocugen remains on course to have two drugs in late-stage testing before the end of the year as its dry eye disease candidate OCU310 clears a phase 2 trial.
Aerie Pharma—just months away from a possible approval for its lead glaucoma drug—is hoping to unlock the potential of a key pipeline compound with help from Netherlands company Royal DSM.